Ginkgo Bioworks Holdings, Inc. (DNA) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DNA Revenue Growth
Revenue Breakdown (FY 2025)
DNA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
DNA Revenue Analysis (2019–2025)
As of May 8, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) generated trailing twelve-month (TTM) revenue of $121.8 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, DNA's 5-year compound annual growth rate (CAGR) stands at +17.3%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $477.7 million in 2022.
Revenue diversification analysis shows DNA's business is primarily driven by Service (100%). With over half of revenue concentrated in Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BEAM (+108.0% YoY), TWST (+17.8% YoY), and SRPT (-2.2% YoY), DNA has underperformed the peer group in terms of revenue growth. Compare DNA vs BEAM →
DNA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DNACurrent | $122M | -100.0% | +17.3% | -185.3% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 TWST | $377M | +17.8% | +33.1% | -36.2% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% |
DNA Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $170.2M | -25.1% | $138.6M | 81.5% | $-315,278,000 | -185.3% |
| 2024 | $227.0M | -9.7% | $188.5M | 83.0% | $-559,757,000 | -246.5% |
| 2023 | $251.5M | -47.4% | $197.4M | 78.5% | $-864,406,000 | -343.8% |
| 2022 | $477.7M | +52.2% | $273.5M | 57.3% | $-2,208,952,000 | -462.4% |
| 2021 | $313.8M | +309.4% | $184.1M | 58.7% | $-1,828,467,000 | -582.6% |
| 2020 | $76.7M | +41.5% | $61.0M | 79.6% | $-137,027,000 | -178.8% |
| 2019 | $54.2M | - | $54.2M | 100.0% | $-71,598,000 | -132.1% |
See DNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DNA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDNA — Frequently Asked Questions
Quick answers to the most common questions about buying DNA stock.
Is DNA's revenue growth accelerating or slowing?
DNA revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +17.3%. TTM revenue fell to $122M. This reverses the prior growth trend.
What is DNA's long-term revenue growth rate?
Ginkgo Bioworks Holdings, Inc.'s 5-year revenue CAGR of +17.3% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is DNA's revenue distributed by segment?
DNA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.